NCT06663111View on ClinicalTrials.gov

Rituximab and Ocrelizumab in Serum With Multiple Sclerosis

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
OTHER

Blood samples for PK

Blood sampled for pharmacokinetic study

OTHER

Blood samples for PK

Blood samples before, shortly after infusion of already assigned/ongoing treatment as well as after 2, 4, 8, 12, 24 weeks for serum conc. measurements.

Trial Locations (1)

5021

RECRUITING

Haukeland University Hospital, Deparment of medical biochemistry and pharmacology, Bergen

All Listed Sponsors
collaborator

University of Bergen

OTHER

lead

Haukeland University Hospital

OTHER